Posted by Michael Wonder on 08 Jun 2022
FDA grants fast track designation for BioCryst’s ALK-2 inhibitor, BCX9250
8 June 2022 - BioCryst Pharmaceuticals today announced the U.S. FDA has granted fast track designation for BCX9250 for the prevention of heterotopic ossification in patients with fibrodysplasia ossificans progressiva.
BCX9250 is designed to inhibit the ALK-2 enzyme, which is a part of the normal signalling pathway for bone formation and responds to binding its specific ligands (bone morphogenic proteins) by stimulating normal bone growth and renewal in healthy children and adults.
